Microba Life Sciences Limited · ASX:MAP
Microba Life Sciences — Shareholder Meeting (November 2022)
18 slides from Microba Life Sciences's shareholder meeting presentation, Nov 25, 2022
Slide 1: 2022 AGM: Chair and Deputy Chair Addresses and CEO Presentation
ASX Announcement 25 November 2022 2022 AGM Chair and Deputy Chair Addresses and CEO Presentation For personal use only Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to attach below the Chair and Deputy Chair’s addresses and the CEO presentation to be delivered at t
Slide 2: Chair – Pasquale Rombola's Address
ASX Announcement 25 November 2022 Chair – Pasquale Rombola’s Address Welcome to the 2022 AGM of Microba Life Sciences. During the meeting, Professor Ian Frazer, Dr. Luke Reid and myself will each address the meeting. It is positive that the Covid-19 pandemic is having a less profound impact on commu
Slide 3: Deputy Chair – Professor Ian Frazer's Address
ASX Announcement 25 November 2022 Deputy Chair – Professor Ian Frazer’s Address This year has been an exciting one for Microba. Research is steadily increasing our understanding of the critical role that our microbiome plays in health. At Microba we are constantly improving our already world leading
Slide 4: Transforming health through the human microbiome
For personal use only Transforming health through the human microbiome 2022 Annual General Meeting November 2022 | Authorised for release by the CEO & Chairman
Slide 5: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). For personal use only Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation.
Slide 6: 2022 Milestones
2022 Milestones September 2021 Bacthera manufacturing partnership signed for IBD therapeutic program For personal use only November 2021 Allergy discovery partnership signed with International Flavours & Fragrances (NYSE: IFF) December 2021 US testing distribution partnership signed with Genova Diag
Slide 7: Investment highlights
Investment highlights For personal use only Company entered next phase Global testing services business Novel therapeutics advancing of development scaling with market leaders into clinical development • Successful transition to ASX • $4.69m FY22 revenue • 3 key therapeutic programs listed company •
Slide 8: Microbiome Services
For personal use only Microbiome Services Driving global revenues and data growth 5
Slide 9: Expanding network of global distribution partners
Expanding network of global distribution partners Distribution agreements executed with global market leaders to distribute microbiome testing solutions For personal use only powered by Microba’s world leading Analysis Platform technology. Update kit Update kit AU & NZ Europe US Middle East AU New N
Slide 10: Testing Services - Recent Milestones
Testing Services - Recent Milestones For personal use only USA OPERATIONS GCC OPERATIONS COMMENCED COMMENCED Distribution partnership Distribution partnership to open US Healthcare to open Middle East market commenced market commenced NEW PRODUCT PARTNERSHIP SIGNED LAUNCHED & COMMENCED Next generati
Slide 11: Global distribution expansion driving growth post COVID
Global distribution expansion driving growth post COVID For personal use only 10 >20 # Distributors COVID-19 impact Leads 9 8 10 7 Qualified opportunities 6 5 4 5 18 Potential new countries 3 3 3 2 2 4 1 Potential new US distributors 0 FY18 FY19 FY20 FY21 FY22 FY23* *growth expected based on establi
Slide 12: Product leadership expanding clinical utility and addressable market
Product leadership expanding clinical utility and addressable market For personal use only MANAGEMENT Healthcare Launched Beta launch Full access Expected 2018 June 2022 Upcoming 2023 Expected 2023 PREVENTION Consumer Health 9
Slide 13: Microbiome Therapeutics
For personal use only Microbiome Therapeutics Developing novel monoclonal microbial cell therapies 10
Slide 14: Key milestones executed advancing towards clinic
Key milestones executed advancing towards clinic For personal use only Inflammatory Bowel Disease Cancer Immunotherapy Autoimmune Diseases PROGRESSING TO PHASE I PRECLINICAL SCREENING Recently Completed Recently Completed Recently Completed Manufacturing scale up Leads discovered Program comme
Slide 15: The start of a therapeutic revolution
The start of a therapeutic revolution For personal use only Q4 CY22 /Q1 CY23 anticipated FDA approval Feacal doner derived enema FDA APPROVAL WOULD CLEAR THE PATH TO MARKET drug product H1 CY23 FOR LIVE MICROBIOME anticipated FDA approval Feacal doner derived oral DRUGS, A NEW MODALITY. capsule drug
Slide 16: Outlook
For personal use only Outlook 13
Slide 17: Upcoming Milestones for FY23
Upcoming Milestones for FY23 2022 2023 2023 For personal use only OCT – DEC JAN - MAR APR - JUN Services New healthcare product full launch Services SYNLAB country expansion Services New international distribution deals Services New international distribution deals Therapeutics - IBD MAP315 program
Slide 18: Contact
Contact For personal use only Dr Luke Reid Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Princess Alexandra Hospital Chairman Woolloongabba QLD Australia pasquale.rombola@microba.com
Microba Life Sciences — Shareholder Meeting (November 2022) on 6ix